{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T08:59:12Z","timestamp":1773737952235,"version":"3.50.1"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.intimp.2021.107376","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T02:12:14Z","timestamp":1613009534000},"page":"107376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Efficacy and cost of different treatment in patients with idiopathic membranous nephropathy: A network meta-analysis and cost-effectiveness analysis"],"prefix":"10.1016","volume":"94","author":[{"given":"Pinyuan","family":"Dai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinfang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Kawuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.intimp.2021.107376_b0005","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2165\/00002512-200724090-00002","article-title":"Membranous nephropathy in the older adult: epidemiology, diagnosis and management","volume":"24","author":"Deegens","year":"2007","journal-title":"Drugs Aging"},{"issue":"9981","key":"10.1016\/j.intimp.2021.107376_b0010","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/S0140-6736(15)60731-0","article-title":"Pathophysiological advances in membranous nephropathy: time for a shift in patient's care","volume":"385","author":"Ronco","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.intimp.2021.107376_b0015","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107376_b0020","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5114\/pjp.2018.79540","article-title":"Membranous glomerulonephritis \u2013 a common, unspecific pattern of glomerular injury","volume":"69","author":"Starzynska-Kubicka","year":"2018","journal-title":"Pol. J. Pathol."},{"issue":"12","key":"10.1016\/j.intimp.2021.107376_b0025","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1681\/ASN.2016010093","article-title":"Long-Term Exposure to Air Pollution and Increased Risk of Membranous Nephropathy in China","volume":"27","author":"Xu","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107376_b0030","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1053\/snep.2003.50023","article-title":"Other immunosuppressive agents for focal segmental glomerulosclerosis","volume":"23","author":"Claudio","year":"2003","journal-title":"Semin. Nephrol."},{"issue":"9","key":"10.1016\/j.intimp.2021.107376_b0035","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2215\/CJN.01330209","article-title":"The natural history of the non-nephrotic membranous nephropathy patient","volume":"4","author":"Hladunewich","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107376_b0040","first-page":"6","article-title":"Management of patients with membranous nephropathy","volume":"27","author":"Hofstra","year":"2012","journal-title":"Eur. Dial. Trans. Assoc."},{"issue":"3","key":"10.1016\/j.intimp.2021.107376_b0045","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.ajkd.2013.06.002","article-title":"KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis","volume":"62","author":"Beck","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.intimp.2021.107376_b0050","article-title":"Risk of infection with different immunosuppressive drugs combined with glucocorticoids for the treatment of idiopathic membranous nephropathy: A pairwise and network meta-analysis","volume":"70(354\u201361","author":"Liu","year":"2019","journal-title":"Int. Immunopharmacol."},{"issue":"11","key":"10.1016\/j.intimp.2021.107376_b0055","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"12","key":"10.1016\/j.intimp.2021.107376_b0060","doi-asserted-by":"crossref","first-page":"i","DOI":"10.3310\/hta3120","article-title":"Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses","volume":"3","author":"Moher","year":"1999","journal-title":"Health Technol. Assess"},{"issue":"2","key":"10.1016\/j.intimp.2021.107376_b0065","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jrsm.57","article-title":"Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions","volume":"3","author":"Chaimani","year":"2012","journal-title":"Res. Synth. Meth."},{"key":"10.1016\/j.intimp.2021.107376_b0070","unstructured":"Drugs and pharmaceutical electronic market information (eMit). www.gov.uk\/government\/publications\/drugs-and-pharmaceutical-electronic-market-information-emit. [M]. (11 November 2020, date last accessed)."},{"key":"10.1016\/j.intimp.2021.107376_b0075","unstructured":"Joint Formulary Committee, British National Formulary, 78th edn. London: BMJ Group and Pharmaceutical Press [M], 2019."},{"key":"10.1016\/j.intimp.2021.107376_b0080","doi-asserted-by":"crossref","DOI":"10.1002\/pd.5803","article-title":"Isolated Echogenic Intracardiac Foci and the Role of Cell-Free Fetal DNA: A Cost-Effectiveness Analysis","author":"Hacker","year":"2020","journal-title":"Prenat. Diagn."},{"issue":"12","key":"10.1016\/j.intimp.2021.107376_b0085","first-page":"2145","article-title":"Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model","volume":"33","author":"Hamilton","year":"2018","journal-title":"Eur. Dial. Trans. Assoc."},{"issue":"12","key":"10.1016\/j.intimp.2021.107376_b0090","first-page":"1518","article-title":"The therapeutic evaluation of tacrolimus combined with glucocorticoids on membranous nephropathy","volume":"39","author":"Abulitibu","year":"2016","journal-title":"J. Xinjiang Med. Univ."},{"issue":"01","key":"10.1016\/j.intimp.2021.107376_b0095","first-page":"11","article-title":"A Comparison on Clinical Curative Effect of Tacrolimus and Cyclophosph with Hormone on Patients with Idiopathic Membranous Nephropathy","volume":"29","author":"Beibei","year":"2016","journal-title":"J. Math. Med."},{"issue":"5","key":"10.1016\/j.intimp.2021.107376_b0100","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/qjmed\/91.5.359","article-title":"Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency","volume":"91","author":"Branten","year":"1998","journal-title":"QJM: Mon. J. Assoc. Phys."},{"issue":"4","key":"10.1016\/j.intimp.2021.107376_b0105","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","article-title":"Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial","volume":"59","author":"Cattran","year":"2001","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.intimp.2021.107376_b0110","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1440-1797.2007.00822.x","article-title":"Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome","volume":"12","author":"Chan","year":"2007","journal-title":"Nephrology (Carlton, Vic)"},{"issue":"3","key":"10.1016\/j.intimp.2021.107376_b0115","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MAJ.0b013e3181ca3a7d","article-title":"Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial","volume":"339","author":"Chen","year":"2010","journal-title":"Am. J. Med. Sci."},{"issue":"13","key":"10.1016\/j.intimp.2021.107376_b0120","first-page":"1910","article-title":"Efficacy of cyclosporin A combined with hormone in treatment of membranous nephropathy","volume":"34","author":"Cheng","year":"2013","journal-title":"J. Qiqihar Univ. Med."},{"issue":"9","key":"10.1016\/j.intimp.2021.107376_b0125","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2018.33.e74","article-title":"The Effect of Mycophenolate Mofetil versus Cyclosporine as Combination Therapy with Low Dose Corticosteroids in High-risk Patients with Idiopathic Membranous Nephropathy: a Multicenter Randomized Trial","volume":"33","author":"Choi","year":"2018","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.intimp.2021.107376_b0130","unstructured":"G. Chunshou, Efficacy of tacrolimus or mycophenolate mofetil combined with hormone in phase III of idiopathic membranous nephropathy manifested with nephrotic syndrome, 2013."},{"issue":"1","key":"10.1016\/j.intimp.2021.107376_b0135","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up","volume":"28","author":"Dahan","year":"2017","journal-title":"J. Am. Soc. Nephrol. JASN"},{"issue":"04","key":"10.1016\/j.intimp.2021.107376_b0140","first-page":"50","article-title":"Clinical study of Cyclophosphamide and Cyclosporine A in the treatment of membranous Nephropathy","volume":"13","author":"Dan","year":"2016","journal-title":"Health Med. Res. Pract."},{"issue":"4","key":"10.1016\/j.intimp.2021.107376_b0145","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1053\/j.ajkd.2008.04.013","article-title":"Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial","volume":"52","author":"Dussol","year":"2008","journal-title":"Am. J. Kidney Dis. Official J. Natl. Kidney Foundation"},{"issue":"8","key":"10.1016\/j.intimp.2021.107376_b0150","first-page":"120","article-title":"Observation on the efficacy of low and small dose cyclosporine in the treatment of idiopathic membranous nephropathy in adults","volume":"41","author":"Fengxun","year":"2014","journal-title":"Chin. J. Pract. Med."},{"issue":"3","key":"10.1016\/j.intimp.2021.107376_b0155","first-page":"270","article-title":"Mycophenolate mofetil combined with prednisone for treatment of idiopathic membranous nephropathy with nephrotic syndrome: a 36-month prospective controlled study","volume":"33","author":"Fu","year":"2012","journal-title":"Acad. J. Second Military Med. Univ."},{"issue":"10","key":"10.1016\/j.intimp.2021.107376_b0160","first-page":"872","article-title":"Efficacy Comparison of Leflunomide and Cyclophosphamine Treatment on Idiopathic Membranous Nephropathy","volume":"12","author":"Guofu","year":"2011","journal-title":"Chin. J. Integrated Traditional Western Nephrol."},{"issue":"06","key":"10.1016\/j.intimp.2021.107376_b0165","first-page":"522","article-title":"Efficacy Comparison of Leflunomide and Cyclophosphamine Treatment on Idiopathic Membranous Nephropathy","volume":"12","author":"Guofu","year":"2011","journal-title":"Chin. J. Integrated Traditional Western Nephrol."},{"key":"10.1016\/j.intimp.2021.107376_b0170","first-page":"3117","article-title":"Study on effect of leflunomide combined with prednisone in treating idiopathic membranous nephropathy","volume":"20","author":"Haihong","year":"2014","journal-title":"Chin. J. Prim. Med. Pharm."},{"issue":"3","key":"10.1016\/j.intimp.2021.107376_b0175","doi-asserted-by":"crossref","first-page":"564","DOI":"10.5301\/jn.5000199","article-title":"Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids","volume":"26","author":"He","year":"2013","journal-title":"J. Nephrol."},{"issue":"09","key":"10.1016\/j.intimp.2021.107376_b0180","first-page":"54","article-title":"Effect of tacrolimus combined with glucocorticoid in the treatment of idiopathic membranous nephropathy and its effect on urinary protein level","volume":"4","author":"Heng","year":"2019","journal-title":"Clin. Res. Pract. I"},{"issue":"07","key":"10.1016\/j.intimp.2021.107376_b0185","first-page":"122","article-title":"Clinical Efficacy of Low-dose Cyclosporine A in the Treatment of Senile Membranous Nephropathy","volume":"11","author":"Hongbing","year":"2019","journal-title":"China Continuing Med. Ed."},{"key":"10.1016\/j.intimp.2021.107376_b0190","first-page":"2467","article-title":"The analysis of short and long term clinical efficacy of cyclosporin and hormone in the treatment of patients with idiopathic membranous nephropathy","volume":"16","author":"Hongting","year":"2015","journal-title":"Chin. J. Prim. Med. Pharm."},{"issue":"6","key":"10.1016\/j.intimp.2021.107376_b0195","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"18","author":"Jha","year":"2007","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"issue":"9","key":"10.1016\/j.intimp.2021.107376_b0200","first-page":"2204","article-title":"Clinical observation of hormone combined with different immunosuppressants in the treatment of Idiopathic membranous Nephropathy caused by High risk factors","volume":"37","author":"Jiabin","year":"2016","journal-title":"Jilin Med. J."},{"issue":"12","key":"10.1016\/j.intimp.2021.107376_b0205","first-page":"1218","article-title":"Clinical observation of leflunomide combined with prednisone acetate in the treatment of idiopathic membranous nephropathy","volume":"25","author":"Jianfa","year":"2011","journal-title":"J. Chin. Pract. Diag. Ther."},{"issue":"01","key":"10.1016\/j.intimp.2021.107376_b0210","first-page":"37","article-title":"Study on the efficacy of glucocorticoid combined with cyclophosphamide in the treatment of membranous nephropathy","volume":"14","author":"Jianrong","year":"2016","journal-title":"Chin. Foreign Med. Res."},{"issue":"16","key":"10.1016\/j.intimp.2021.107376_b0215","first-page":"117","article-title":"Clinical Value of Low Dose Prednisone Combined With Tacrolimus in the Treatment for Idiopathic Membranous Nephropathy","volume":"10","author":"Jingying","year":"2018","journal-title":"China Continuing Med. Ed."},{"issue":"11","key":"10.1016\/j.intimp.2021.107376_b0220","first-page":"55","article-title":"Application of Rituximab in the Treatment of Idiopathic Membranous Nephropathy","volume":"4","author":"Jinling","year":"2019","journal-title":"Syst. Med."},{"issue":"07","key":"10.1016\/j.intimp.2021.107376_b0225","first-page":"96","article-title":"Idiopathic membranous nephropathyEffect observation of prednisone combined with cyclophosphamide in the treatment of patients with","volume":"7","author":"Juan","year":"2015","journal-title":"Chin. J. Front. Med. Sci. (Electronic Version)"},{"issue":"08","key":"10.1016\/j.intimp.2021.107376_b0230","first-page":"716","article-title":"Long-term efficacy of Cyclophosphamide combined with Cyclosporine A in the treatment of membranous Nephropathy","volume":"15","author":"Juan","year":"2014","journal-title":"Chin. J. Integrated Traditional Western Nephrol."},{"issue":"5","key":"10.1016\/j.intimp.2021.107376_b0235","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3109\/08860221003728754","article-title":"Comparison of immunosuppressive therapeutic regimens in patients with nephrotic syndrome due to idiopathic membranous nephropathy","volume":"32","author":"Kosmadakis","year":"2010","journal-title":"Ren. Fail."},{"key":"10.1016\/j.intimp.2021.107376_b0240","series-title":"Long-term efficacy and safety of cyclosporine combined with glucocorticoid in the treatment of idiopathic membranous nephropathy","author":"Lanlan","year":"2017"},{"issue":"12","key":"10.1016\/j.intimp.2021.107376_b0245","first-page":"1238","article-title":"Effect of tacrolimus on serum creatinine, serum albumin and 24-hour urinary protein in patients with membranous nephropathy","volume":"15","author":"Li","year":"2016","journal-title":"Chin. J. Diffic. Compl Cas"},{"issue":"7","key":"10.1016\/j.intimp.2021.107376_b0250","first-page":"797","article-title":"Efficacy and safety of tacrolimus versus cyclosporine in adults with idiopathic membranous nephropathy","volume":"17","author":"Li","year":"2012","journal-title":"Chin. J. Clin. Pharmacol. Therap."},{"issue":"1","key":"10.1016\/j.intimp.2021.107376_b0255","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1080\/0886022X.2017.1325371","article-title":"The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"39","author":"Liang","year":"2017","journal-title":"Ren. Fail."},{"issue":"1","key":"10.1016\/j.intimp.2021.107376_b0260","first-page":"94","article-title":"Efficacy of leflunomide combined with low dose prednisone in the treatment of idiopathic membranous nephropathy","volume":"35","author":"Ligang","year":"2014","journal-title":"Anhui Med. J."},{"issue":"9","key":"10.1016\/j.intimp.2021.107376_b0265","first-page":"659","article-title":"Effects of cyclosporine and leflunomide combined with low-dose prednisone in the treatment of idiopathic membranous nephropathy","volume":"29","author":"Lin","year":"2013","journal-title":"Chin. J. Clin. Pharmacol."},{"issue":"05","key":"10.1016\/j.intimp.2021.107376_b0270","first-page":"90","article-title":"Observation on the clinical effect of tacrolimus in the treatment of idiopathic membranous nephropathy","volume":"18","author":"Lin","year":"2014","journal-title":"J. Clin. Med. Pract."},{"issue":"13","key":"10.1016\/j.intimp.2021.107376_b0275","article-title":"Efficacy of Cyclophosphamide or Cyclosporine A Combined with Glucocorticoids in the Treatment of Idiopathic Membranous Nephropathy","volume":"17","author":"Li-Na","year":"2019","journal-title":"Guide China Med."},{"issue":"16","key":"10.1016\/j.intimp.2021.107376_b0280","first-page":"180","article-title":"Clinical comparison of hormone combined with different immunosuppressants in the treatment of Idiopathic membranous Nephropathy","volume":"14","author":"Linlin","year":"2016","journal-title":"Guide China Med."},{"issue":"31","key":"10.1016\/j.intimp.2021.107376_b0285","first-page":"97","article-title":"Clinical Observation of Adult With Idiopathic Membranous Nephropathy by Tacrolimus United Hormone","volume":"6","author":"Management","year":"2015","journal-title":"LIN Zheng"},{"issue":"01","key":"10.1016\/j.intimp.2021.107376_b0290","first-page":"121","article-title":"Clinical observation of cyclophosphamide combined with glucocorticoid on membranus nephropathy","volume":"36","author":"Min","year":"2016","journal-title":"Chin. J. Biochem. Pharm."},{"key":"10.1016\/j.intimp.2021.107376_b0295","first-page":"140","article-title":"Clinical study of Mycophenolate mofetil or Cyclophosphamide combined with hormone in the treatment of Idiopathic membranous Nephropathy","volume":"20","author":"Mingsheng","year":"2014","journal-title":"Chin. J. Trauma Disab. Med."},{"key":"10.1016\/j.intimp.2021.107376_b0300","series-title":"Clinical effects of tacrolimus Division combined with glucocorticoids on the treatment of idiopathic membranous nephropatny","author":"Na","year":"2013"},{"issue":"1","key":"10.1016\/j.intimp.2021.107376_b0305","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jfma.2015.07.021","article-title":"Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy","volume":"115","author":"Peng","year":"2016","journal-title":"J. Formosan Med. Assoc. = Taiwan yi zhi"},{"key":"10.1016\/j.intimp.2021.107376_b0310","series-title":"The Long-term Efficacy And Safety Study of Tacrolimus Combined With Corticosteroids In The Treatment of Idiopathic Membranous Nephropathy","author":"Ping","year":"2015"},{"issue":"3","key":"10.1016\/j.intimp.2021.107376_b0315","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.V93444","article-title":"A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy","volume":"9","author":"Ponticelli","year":"1998","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"issue":"2","key":"10.1016\/j.intimp.2021.107376_b0320","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.ajkd.2005.10.016","article-title":"A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy","volume":"47","author":"Ponticelli","year":"2006","journal-title":"Am. J. Kidney Dis. Official J. Natl. Kidney Foundation"},{"issue":"15","key":"10.1016\/j.intimp.2021.107376_b0325","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1056\/NEJM198404123101503","article-title":"Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy","volume":"310","author":"Ponticelli","year":"1984","journal-title":"New England J. Med."},{"issue":"9","key":"10.1016\/j.intimp.2021.107376_b0330","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJM199208273270904","article-title":"Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group","volume":"327","author":"Ponticelli","year":"1992","journal-title":"New England J. Med."},{"issue":"9","key":"10.1016\/j.intimp.2021.107376_b0335","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/sj.ki.5002215","article-title":"Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial","volume":"71","author":"Praga","year":"2007","journal-title":"Kidney Int."},{"key":"10.1016\/j.intimp.2021.107376_b0340","series-title":"Clinical study of tacrolimus and cyclosporine combined with semiquantitative glucocorticoid in the treatment of idiopathic membranous nephropathy","author":"Qingfeng","year":"2016"},{"issue":"06","key":"10.1016\/j.intimp.2021.107376_b0345","first-page":"6","article-title":"Therapeutic effect of cyclophosphamide combined with glucocorticoid on patients with idiopathic membranous nephropathy with nephrotic syndrome","volume":"31","author":"Qingtong","year":"2018","journal-title":"Acta Med. Sin."},{"issue":"2","key":"10.1016\/j.intimp.2021.107376_b0350","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/nep.12569","article-title":"Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial","volume":"21","author":"Ramachandran","year":"2016","journal-title":"Nephrology (Carlton, Vic)"},{"issue":"08","key":"10.1016\/j.intimp.2021.107376_b0355","first-page":"1077","article-title":"Clinical observation of tacrolimus combined with methylprednisone in the treatment of idiopathic membranous nephropathy","volume":"29","author":"Rongfang","year":"2017","journal-title":"Modern Pract. Med."},{"issue":"10","key":"10.1016\/j.intimp.2021.107376_b0360","article-title":"Clinical study of tacrolimus combined with glucocorticoid in the treatment of membranous nephropathy","volume":"22","author":"Ruiheng","year":"2016","journal-title":"Med. Recapitulate"},{"issue":"6","key":"10.1016\/j.intimp.2021.107376_b0365","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1093\/ndt\/gfm538","article-title":"Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study","volume":"23","author":"Senthil Nayagam","year":"2008","journal-title":"Eur. Dialysis Transplant Assoc."},{"issue":"14","key":"10.1016\/j.intimp.2021.107376_b0370","first-page":"125","article-title":"Clinical study of Cyclosporine A and Cyclophosphamide in the treatment of Idiopathic membranous Nephropathy","volume":"12","author":"Shanshan","year":"2018","journal-title":"Chin. J. Mod. Drug Appl."},{"issue":"15","key":"10.1016\/j.intimp.2021.107376_b0375","first-page":"2040","article-title":"Efficacy Observation of Cyclophosphamide, Leflunomide Sequentially Combined with Prednisone in the Treatment of Membranous Nephropathy in Stage \u2161","volume":"27","author":"Shuzhen","year":"2016","journal-title":"China Pharm."},{"issue":"02","key":"10.1016\/j.intimp.2021.107376_b0380","article-title":"Comparison of efficacy and safety between tacrolimus and leflunomide in the treatment of idiopathic membranous nephropathy","volume":"25","author":"Tian-Qi","year":"2018","journal-title":"China Modern Med."},{"issue":"12","key":"10.1016\/j.intimp.2021.107376_b0385","first-page":"1889","article-title":"Clinical traiI on the effect of leflunomide in treating primary membranous nephropathy","volume":"30","author":"Wei","year":"2009","journal-title":"Sichuan Med. J."},{"issue":"1","key":"10.1016\/j.intimp.2021.107376_b0390","first-page":"32","article-title":"Clinical triaI on the effect of mycophenolate mofetil and prednisone in treating primary membranous nephropathy","volume":"31","author":"Wei","year":"2010","journal-title":"Sichuan Med. J."},{"issue":"2","key":"10.1016\/j.intimp.2021.107376_b0395","first-page":"109","article-title":"Combination therapy of prednisone and cyclophosphamide for patients with idiopathic membranous nephropathy:a prospective randomized controlled trial","volume":"21","author":"Wu","year":"2012","journal-title":"Chin. J. Nephrol. Dialysis Transpl."},{"key":"10.1016\/j.intimp.2021.107376_b0400","series-title":"Clinical Observation of the Tacrolimus Therapy in 30 Cases of Membranous Nephropathy","author":"Xiaojuan","year":"2013"},{"issue":"04","key":"10.1016\/j.intimp.2021.107376_b0405","first-page":"255","article-title":"The efficacy of tacrolimus acts on angiopoietin-like protein-4 in treatment of membranous nephropathy","volume":"40","author":"Xiaoli","year":"2018","journal-title":"Acta Acad. Med. Weifang"},{"issue":"03","key":"10.1016\/j.intimp.2021.107376_b0410","article-title":"Clinical Effect of Tacrolimus Combined with Glucocorticoid on Idiopathic Membranous Nephropathy","volume":"16","author":"Xi-Feng","year":"2019","journal-title":"Drug Eval. Res."},{"issue":"05","key":"10.1016\/j.intimp.2021.107376_b0415","first-page":"818","article-title":"Comparison on efficacy and safety of tacrolimus and leflunomide combined with hormone in treatment of idiopathic membranous nephropathy","volume":"39","author":"Xiong","year":"2016","journal-title":"Drug Eval. Res."},{"issue":"23","key":"10.1016\/j.intimp.2021.107376_b0420","article-title":"Clinical Observation of Leflunomide Combined with Prednison in the Treatment of Membranous Nephropathy","volume":"27","author":"Yali","year":"2016","journal-title":"China Pharmacy"},{"issue":"12","key":"10.1016\/j.intimp.2021.107376_b0425","first-page":"65","article-title":"Effect of Mycophenolate Mofetil on Primary Membranous Nephmpathy","volume":"10","author":"Yang","year":"2019","journal-title":"China Health Standard Manage."},{"issue":"35","key":"10.1016\/j.intimp.2021.107376_b0430","first-page":"7179","article-title":"Efficacy and safety of tacrolimus and cyclophosphamide in the treatment of idiopathic membranous nephropathy","volume":"2","author":"Yi","year":"2015","journal-title":"J. Clinical Med."},{"issue":"5","key":"10.1016\/j.intimp.2021.107376_b0435","first-page":"595","article-title":"Efficacy and safety of Mycophenolate mofetile combined with hormone in the treatment of membranous nephropathy","volume":"07","author":"Yong","year":"2012","journal-title":"China Med."},{"issue":"17","key":"10.1016\/j.intimp.2021.107376_b0440","first-page":"2739","article-title":"Clinical effect of mycophenolate mofetil combined with hormone in the treatment of membranous nephropathy","volume":"29","author":"Yongfeng","year":"2018","journal-title":"Mod. Diagn. Treat."},{"issue":"15","key":"10.1016\/j.intimp.2021.107376_b0445","first-page":"4","article-title":"Analysis of clinical effect by tacrolimus for idiopathic membranous nephropathy","volume":"10","author":"Zhi-Xin","year":"2015","journal-title":"China Prac. Med."},{"issue":"16","key":"10.1016\/j.intimp.2021.107376_b0450","article-title":"Comparison on the therapeutic effect of cyclosporin A and cyclophosphamide in the treatment of idiopathic membranous nephropathy","volume":"4","author":"Zhongfeng","year":"2014","journal-title":"China Med. Pharm."},{"issue":"22","key":"10.1016\/j.intimp.2021.107376_b0455","first-page":"2181","article-title":"Prognosis of tacrolimus combined with prednisone on patients with idiopathic membranous nephropathy","volume":"31","author":"Zhou","year":"2015","journal-title":"Chin. J. Clinical Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107376_b0460","first-page":"59","article-title":"Efficacy of mycophenolate mofetil combined with low dose hormone in the treatment of membranous nephropathy","volume":"12","author":"Zhu","year":"2011","journal-title":"Chin. J. Integrated Traditional Western Nephrol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107376_b0465","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.nefro.2018.10.008","article-title":"A comparison of cyclophosphamide versus tacrolimus in terms of treatment effect for idiopathic membranous nephropathy: A meta-analysis","volume":"39","author":"Li","year":"2019","journal-title":"Nefrologia"},{"issue":"3","key":"10.1016\/j.intimp.2021.107376_b0470","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0272-6386(04)00809-1","article-title":"Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review","volume":"44","author":"Perna","year":"2004","journal-title":"Am. J. Kidney Diseases: Official J. Natl. Kidney Foundation"},{"issue":"2","key":"10.1016\/j.intimp.2021.107376_b0475","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.autrev.2016.12.005","article-title":"Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: A systematic review and meta-analysis of 21 clinical trials","volume":"16","author":"Qiu","year":"2017","journal-title":"Autoimmun. Rev."},{"issue":"11","key":"10.1016\/j.intimp.2021.107376_b0480","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1097\/00007890-200206150-00019","article-title":"Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production","volume":"73","author":"Jiang","year":"2002","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.intimp.2021.107376_b0485","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1053\/ajkd.1998.v31.pm9469489","article-title":"Successful mycophenolate mofetil treatment of glomerular disease","volume":"31","author":"Briggs","year":"1998","journal-title":"Am. J. Kidney Diseases: Official J. Natl. Kidney Foundation"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921000126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921000126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:30:19Z","timestamp":1761586219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921000126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":97,"alternative-id":["S1567576921000126"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107376","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and cost of different treatment in patients with idiopathic membranous nephropathy: A network meta-analysis and cost-effectiveness analysis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107376","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107376"}}